Circassia Pharmaceuticals plc announced it has entered into a definitive agreement to acquire the exclusive commercialisation rights from AIT Therapeutics Inc. to its ventilator compatible nitric oxide product, AirNOvent, in the United States and China. The rights cover all potential indications in the hospital setting for the administration of inhaled nitric oxide at up to 80 parts per million, which includes hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn. AIT anticipates applying to the US Food and Drug Administration (FDA) for Premarket Approval (PMA) for AirNOvent in Second Quarter 2019 for use in the treatment of PPHN, and the Company anticipates launching the product in the first half of 2020, once approved. Subsequently, AIT plans to seek a label extension for the product's use in a related indication.